-
EP4415758
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4415758
| EP4415758 - PHARMACEUTICAL COMPOSITIONS OF EFRUXIFERMIN [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 19.07.2024 Database last updated on 30.03.2026 | |
| Former | The international publication has been made Status updated on 03.05.2023 | ||
| Former | unknown Status updated on 16.11.2022 | Most recent event Tooltip | 13.09.2025 | New entry: Renewal fee paid | Applicant(s) | For all designated states Akero Therapeutics, Inc. 601 Gateway Blvd., Suite 350 South San Francisco, CA 94080 / US | [2024/34] | Inventor(s) | 01 /
DIMITROVA, Mariana, N. San Francisco, CA 94080 / US | 02 /
ROLPH, Timothy, P. San Francisco, CA 94080 / US | 03 /
EISELE, Simon 82152 Martinsried / DE | 04 /
BOSTICK, James 82152 Martinsried / DE | [2024/34] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [2024/34] | Application number, filing date | 22800978.3 | 12.10.2022 | [2024/34] | WO2022US77968 | Priority number, date | US202163255286P | 13.10.2021 Original published format: US 202163255286 P | [2024/34] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2023064808 | Date: | 20.04.2023 | Language: | EN | [2023/16] | Type: | A1 Application with search report | No.: | EP4415758 | Date: | 21.08.2024 | Language: | EN | The application published by WIPO in one of the EPO official languages on 20.04.2023 takes the place of the publication of the European patent application. | [2024/34] | Search report(s) | International search report - published on: | EP | 20.04.2023 | Classification | IPC: | A61K47/18, A61K47/26, A61K38/18, A61K47/68, A61K9/08, A61K9/19 | [2024/34] | CPC: |
A61K9/19 (EP,IL,KR,US);
A61K38/1825 (EP,IL,KR,MA,US);
A61K9/0019 (EP,IL,KR);
A61K47/02 (US);
A61K47/12 (US);
A61K47/18 (EP,IL,KR,US);
A61K47/183 (EP,IL,KR,MA,US);
A61K47/22 (US);
A61K47/26 (EP,IL,KR,US);
A61K47/38 (US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/34] | Title | German: | PHARMAZEUTISCHE ZUSAMMENSETZUNGEN AUS ETRUXIFERMIN | [2024/34] | English: | PHARMACEUTICAL COMPOSITIONS OF EFRUXIFERMIN | [2024/34] | French: | COMPOSITIONS PHARMACEUTIQUES D'EFRUXIOL | [2024/34] | Entry into regional phase | 30.04.2024 | National basic fee paid | 30.04.2024 | Designation fee(s) paid | 30.04.2024 | Examination fee paid | Examination procedure | 30.04.2024 | Examination requested [2024/34] | 30.04.2024 | Date on which the examining division has become responsible | 22.11.2024 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 12.09.2024 | Renewal fee patent year 03 | 12.09.2025 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [YD] WO2010129503 (AMGEN INC et al.) | [Y] CN111195234 (LUNAN PHARMACEUTICAL GROUP CORP et al.) | [A] RANDY HECHT ET AL: "Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes", PLOS ONE, vol. 7, no. 11, 27 November 2012 (2012-11-27), pages e49345, XP055192704, DOI: 10.1371/journal.pone.0049345 DOI: http://dx.doi.org/10.1371/journal.pone.0049345 | [A] HAN MEI ET AL: "Immunoaffinity capture coupled with capillary electrophoresis - mass spectrometry to study therapeutic protein stabilityin vivo", ANALYTICAL BIOCHEMISTRY, vol. 539, 10 October 2017 (2017-10-10), pages 118 - 126, XP085264924, ISSN: 0003-2697, DOI: 10.1016/J.AB.2017.10.005 DOI: http://dx.doi.org/10.1016/j.ab.2017.10.005 | by applicant | US8034770 | US8410051 | US8642546 | US8361963 | US9273106 | US10011642 | US8188040 | US8835385 | US8795985 | US8618053 | US11072640 | WO2009149171 | WO2010129503 | HECHT ET AL., PLOS ONE, vol. 7, no. 11, 2012, pages e49345 | STANISLAUS ET AL., ENDOCRINOLOGY, vol. 158, no. 5, 2017, pages 1314 - 1327 | KLEINER D ET AL., HEPATOLOGY, vol. 41, 2005, pages 1313 | CHALASANI ET AL., HEPATOLOGY, vol. 67, no. 1, 2018, pages 328 - 357 | HARRISON ET AL., NAT MEDICINE, vol. 27, 2021, pages 1262 - 1271 | BALESTRONI ET AL., MONALDI ARCH CHEST DIS, vol. 78, no. 3, September 2012 (2012-09-01), pages 155 - 9 | YOUNOSSI ET AL., CLIN GASTROENTEROL HEPATOL, vol. 17, no. 10, September 2019 (2019-09-01), pages 2093 - 2100 | INGLE R.FANG W., INT. JOURNAL OF PHARMACEUTICS, vol. 597, 2021, pages 12031 | "Molecular Cloning: A Laboratory Manual", vol. 1-3, 2001, COLD SPRING HARBOR LABORATORY PRESS | OGAWA ET AL., PROC. NATL. ACAD. SCI. U. S. A., vol. 104, pages 7432 - 7437 | AGRAWAL ET AL., MOL METAB, vol. 13, 2018, pages 45 - 55 | YIE ET AL., FEBS LETT, vol. 583, pages 19 - 24 | ORNITZITOH, WILEY INTERDISCIP REV DEV BIOL, vol. 4, no. 3, 2015, pages 215 - 66 | ZOU ET AL., MOL MED REP, vol. 19, no. 2, February 2019 (2019-02-01), pages 759 - 770 |